epilepsy
Conditions
Interventions
None listed
Sponsors
Graduates School of Biomedical Sciences, Department of Neurosurgery, Hiroshima University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with pharmacoresistent partial seizures. Patients with a planning or already performed epileptic surgery. Patients on medication with more than one antiepileptic drugs. Patients given a written informed consent.
Exclusion criteria
Exclusion criteria: Patients already administered levetiracetam before starting the test drugs. Patients with a history of hypersensitivity for ingredients of the test drugs or pyrrolidone derivatives. Patients with psychiatric disease, progressive neurological disorder and other serious complications. Patients during administering other investigational or unapproved drugs within three months before starting a follow-up. Patients with clinical trials of levetiracetam in the past. Patients with levetiracetam discontinued because of the side effects in the past. Patients with non (or potential of non)-compliance to regular medication or doctor consultation appointments. Pregnant or potentially pregnant women, breast-feeding women. Patients considered to be inappropriative for carrying out the trials by attending physicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Long-term tolerability of levetiracetam in patients with epilepsy surgery | — |
Countries
Japan
Outcome results
None listed